Compare Gemini Space Station Inc (GEMI) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gemini Space Station Inc vs ResMed Inc. — how do they compare? Gemini Space Station Inc trades at $4.43 (market cap $579.55M), while ResMed Inc. trades at $230.12 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 55× Gemini Space Station Inc's market cap, and ResMed Inc. pays a 1.16% dividend while Gemini Space Station Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gemini Space Station Inc for 14 Days and ResMed Inc. for 51 Days on average.
| GEMI | RMD | |
|---|---|---|
Market Cap | $579.55M | $31.89B |
Volume | 1,882,406 | 618,314 |
Sector | Financials | Health |
52-Week High | $25.41 | $277.88 |
52-Week Low | $3.54 | $182.82 |
Typical Hold Time | 14 Days | 51 Days |
Enterprise Value | $558.57M | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gemini Space Station (GEMI) trades at $4.40, down 2% today amid bearish technical signals and persistent financial losses. The company reported Q2 2026 revenue growth of 37% year-over-year but missed earnings expectations with a net loss of -$0.89 per share. Despite expanding services revenue and new product offerings, negative profit margins and cash flow challenges persist. Technical indicators show oversold conditions with RSI readings below 11, while moving averages signal continued downward pressure.
The stock faces significant fundamental headwinds with negative margins and cash burn, though analyst consensus suggests 19% upside to the $5.25 price target. Key risks include ongoing litigation, competitive pressures in financial services, and the company's ability to achieve profitability. Recent SEC approval for tokenized stock trading could provide growth opportunities if execution improves.
ResMed (RMD) trades at $230.91, up 2.18% today, with a bullish technical signal and strong fundamentals. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $2.68. Revenue grew to $5.15B in 2025, with a net income margin of 26.94%. Analyst consensus is a buy, with a $242.70 price target. Recent news highlights EPS growth targets of 12%-14% and participation in investor conferences.
Outlook is positive due to robust earnings growth and market share gains, but risks include competitive pressures and regulatory investigations. The stock offers upside to the consensus target, supported by institutional buying and solid cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gemini Space Station Inc
Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.
Read more on GEMI →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
